Mission BioCapital
VC Fund
Cambridge, United States
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
- Total investments:
- 96
- Last investment:
- Lead investor:
- 23%
- Fund size:
- $275M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Mission BioCapital invests in
Stages Mission BioCapital invests in
Countries Mission BioCapital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Series A
- $4.2M–$80M
- Series B
- $21M–$112M
- Venture - Series Unknown
- $2M–$70M
Investment Focus
Industry
- Biotechnology 60 (63%)
- Health Care 35 (36%)
- Therapeutics 27 (28%)
- Medical 18 (19%)
- Life Science 7 (7%)
Stage
- Series A 25 (26%)
- Series B 18 (19%)
- Venture - Series Unknown 17 (18%)
- Seed 12 (13%)
- Pre-Seed 7 (7%)
Country
- United States 66 (69%)
- Switzerland 2 (2%)
- France 1 (1%)
- Germany 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Douglas Crawford
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
Eric W. Linsley
Managing General Partner; Managing General Partner
|
Managing General Partner; Managing General Partner | Total investments: 7 | Find email | |
Johannes Fruehauf
General Partner, Co-Founder
|
General Partner, Co-Founder | Total investments: 7 | Find email | |
Johannes Fruehauf
General Partner and Co-Founder
|
General Partner and Co-Founder | Total investments: 0 | Find email | |
Peter Parker
Managing General Partner
|
Managing General Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases. | $76.7M / Series A / Sep 29, 2026 | ||
| Cloverleaf Bio develops an RNA therapeutic platform for oncology. | $33M / Seed / Sep 08, 2026 | ||
| Deck Bio develops multi-target T cell engager immunotherapies for solid tumors. | $3.1M / Seed / Apr 09, 2026 | ||
| Beech Biotech is utilizing cutting-edge biology to develop innovative therapies for preeclampsia and other pregnancy-related issues. This business extends pregnancy and lessens the effects of premature birth. | $500K / Seed / Apr 02, 2026 | ||
| Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M / Seed / Jan 08, 2026 | ||
| EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | ||
| Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M / Series B / Jan 07, 2026 | ||
| AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $42.5M / Series A / Nov 19, 2025 | ||
| Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M / Series A / Oct 28, 2025 | ||
| Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines. Founded in 2021, the company is based in Boston, Massachusetts. | $25M / Series A / Aug 29, 2025 | ||
| See all 96 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Mission BioCapital invest in?
Mission BioCapital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 96 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mission BioCapital's check size?
Mission BioCapital typically joins rounds of $4.2M–$80M at Series A, $21M–$112M at Series B and $2M–$70M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mission BioCapital participates in.
How do I contact Mission BioCapital?
Public channels for Mission BioCapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mission BioCapital?
The team at Mission BioCapital includes Douglas Crawford (Managing Partner), Eric W. Linsley (Managing General Partner; Managing General Partner) and Johannes Fruehauf (General Partner, Co-Founder), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
